[Market Focus] Genomictree Expands Infrastructure with 10 Billion Won Investment... Targeting 1.9 Trillion Won European Market

Genomictree is showing strong performance. This is interpreted as being influenced by the news that the company has decided to invest 10 billion won in production infrastructure.

As of 9:10 a.m. on January 27, Genomictree was trading at 25,300 won, up 5.86% from the previous day.

On this day, Genomictree announced that it had decided to invest approximately 10 billion won in research, testing, and production infrastructure to accelerate its entry into the global cancer diagnostics market.

Genomictree has built trust in domestic and international medical fields through its differentiated precision cancer diagnostic technologies and services. The company is currently at a critical stage of business transformation to become a leading global cancer diagnostics company. In particular, with the domestic Ministry of Food and Drug Safety's manufacturing approval for its bladder cancer diagnostic test and the acquisition of the European CE-IVDR certification, Genomictree is actively expanding beyond the domestic market into Europe and other global markets. In addition, the company is steadily advancing ongoing clinical trials and approval processes with the U.S. FDA, thereby strengthening its foundation for global commercialization.

This infrastructure investment is a strategic decision to respond to increasing testing demand and to secure the necessary foundation for global market expansion. The company plans to construct a new headquarters and specialized testing center with a total floor area of approximately 5,300 square meters in Dungok District, establishing infrastructure that encompasses research, testing, and production functions. The facility is scheduled to begin construction in the first half of this year after completing the necessary procedures and will be built as an integrated infrastructure covering the entire process from research to production.

Once the infrastructure is completed, the company's testing capacity will expand sixfold, from the current annual processing of approximately 200,000 samples to up to 1.2 million samples. The company explained that this scale will allow it to stably meet initial demand in the domestic and European markets and flexibly respond to future global market expansion.

Furthermore, the infrastructure will serve as a hub for continuously generating and managing empirical data required for European insurance reimbursement and global market expansion. In particular, by establishing an environment that meets GMP standards, the company plans to respond stably to changes in global regulations.

Currently, annual demand for bladder cancer diagnostics in Korea is estimated at about 400,000 to 500,000 cases. According to Grand View Research, the European bladder cancer diagnostics market is expected to reach approximately 1.9 trillion won by 2030, with the molecular diagnostics segment accounting for about 380 billion won. This investment is evaluated as a strategic and planned move to secure a leading position in this increasingly visible global market demand.

An Sungwhan, CEO of Genomictree, emphasized, "This infrastructure investment is a long-term cornerstone for securing global business competitiveness," adding, "We will continue to practice responsible management by sharing the results of increased corporate value with our shareholders."